Does VKTX, SKYE & JANX have room to rally after rallying 269%?
Shares of three biotech stocks, $Viking Therapeutics(VKTX)$$Skye Bioscience Inc.(SKYE)$$Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
04-04
[Amend]Public Prospectus
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]